无驱动基因改变的IV期非小细胞肺癌的治疗：美国临床肿瘤学会生存指南，2023.3版

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.

作者信息

Jaiyesimi Ishmael A, Leighl Natasha B, Ismaila Nofisat, Alluri Krishna, Florez Narjust, Gadgeel Shirish, Masters Gregory, Schenk Erin L, Schneider Bryan J, Sequist Lecia, Singh Navneet, Bazhenova Lyudmila, Blanchard Elizabeth, Freeman-Daily Janet, Furuya Naoki, Halmos Balazs, Azar Ibrahim Hanna, Kuruvilla Sara, Mullane Michael, Naidoo Jarushka, Reuss Joshua E, Spigel David R, Owen Dwight H, Patel Jyoti D

机构信息

Corewell Health William Beaumont University Hospital, Royal Oak and Oakland University William Beaumont School of Medicine, Rochester, MI.

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

出版信息

J Clin Oncol. 2024 Apr 10;42(11):e23-e43. doi: 10.1200/JCO.23.02746. Epub 2024 Feb 28.

DOI:10.1200/JCO.23.02746

PMID:38417098

Abstract

PURPOSE

To provide evidence-based recommendations for patients with stage IV non-small cell lung cancer (NSCLC) without driver alterations.

METHODS

This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized clinical trials (RCTs), with the latest time frame spanning February to October 2023. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened. The literature search included systematic reviews, meta-analyses, and randomized controlled trials. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

RESULTS

This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Ten new RCTs were identified in the latest search of the literature to date.

RECOMMENDATIONS

Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations.Additional information is available at www.asco.org/living-guidelines.

摘要

目的

为无驱动基因改变的IV期非小细胞肺癌（NSCLC）患者提供基于证据的推荐。

方法

本美国临床肿瘤学会（ASCO）实用指南基于对随机临床试验（RCT）的持续系统评价提供不断更新的推荐，最新时间范围为2023年2月至10月。召集了一个由医学肿瘤学、肺病学、社区肿瘤学、研究方法学和宣传专家组成的专家小组。文献检索包括系统评价、荟萃分析和随机对照试验。感兴趣的结果包括疗效和安全性。专家小组成员利用现有证据和非正式共识制定基于证据的指南推荐。